Physician profile
Thomas Adamkiewicz
NPI 1750381612
$1,564.37
in general payments reported to CMS, 2019-2025
13 companies · $627 in 2025
The $627 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.22 · 2020: $32.10 · 2021: $209 · 2022: $280 · 2023: $160 · 2024: $217 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $340.46 | 2019-2025 | |
| Emmaus Medical, INC. | $215.97 | 2020-2022 | |
| Glaxosmithkline, LLC. | $196.45 | 2019-2025 | Penmenvy, Bexsero |
| Global Blood Therapeutics, INC. | $154.07 | 2022 | |
| Agios Pharmaceuticals, INC. | $140.75 | 2025 | Pyrukynd |
| Kowa Pharmaceuticals America, INC. | $135.71 | 2025 | Zoryve |
| Genzyme Corporation | $125.00 | 2025 | |
| Sanofi Pasteur INC. | $119.61 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $69.24 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Novartis Pharmaceuticals Corporation | $21.86 | 2022 | |
| Kyowa Kirin, INC. | $18.04 | 2024 | Crysvita |
| Phadia US INC. | $14.50 | 2020 | |
| Cranial Technologies, INC | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Adamkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.